随着新一代生物药物形态不断向复杂化、多功能化演进,研发与制造端所面临的技术挑战也在同步上升。近日,处于临床阶段的Biotech公司汉康生技(HanchorBio)与CRDMO企业药明生物宣布达成战略合作,双方将围绕多款双功能及多功能融合蛋白项目展开协作,共同推进相关项目从早期临床转化至后期生产阶段。该合作于2026年1月26日正式对外公布。根据协议内容,药明生物将为汉康生技提供一体化生物药服务,...
Source Link随着新一代生物药物形态不断向复杂化、多功能化演进,研发与制造端所面临的技术挑战也在同步上升。近日,处于临床阶段的Biotech公司汉康生技(HanchorBio)与CRDMO企业药明生物宣布达成战略合作,双方将围绕多款双功能及多功能融合蛋白项目展开协作,共同推进相关项目从早期临床转化至后期生产阶段。该合作于2026年1月26日正式对外公布。根据协议内容,药明生物将为汉康生技提供一体化生物药服务,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.